12/04/20 8:00 AMNYSE : LLY, UNHLilly and UnitedHealth Group partner on pragmatic study of neutralizing antibody bamlanivimab (LY-CoV555) for COVID-19Eli Lilly and Company (NYSE: LLY) and UnitedHealth Group (NYSE: UNH) today announced a partnership to conduct a pragmatic study of bamlanivimab (LY-CoV555) in high-risk, COVID-19 infected individuals.Bamlanivimab recently receivedRHEA-AIneutral
12/02/20 4:30 PMNYSE : LLYLilly announces 650,000 additional doses of neutralizing antibody bamlanivimab (LY-CoV555) purchased by U.S. government to treat COVID-19The U.S. government has purchased 650,000 additional doses of Eli Lilly and Company's (NYSE: LLY) neutralizing antibody bamlanivimab (LY-CoV555) 700 mg. The purchase agreement is for $812.5 million and the doses will be delivered through January 31, 2021,RHEA-AIneutral
11/24/20 3:00 PMNYSE : LLYLilly to Participate in Evercore ISI 3rd Annual HealthCONx ConferenceEli Lilly and Company (NYSE: LLY) will participate in the Evercore ISI 3 rd Annual HealthCONx Conference on Tuesday, December 1, 2020. Michael Mason, Lilly senior vice president and president of Lilly Diabetes and Connected Care, will participate in aRHEA-AIneutral
11/20/20 4:23 PMNYSE : LLYLilly's neutralizing antibody bamlanivimab (LY-CoV555) receives interim authorization from Health Canada as a treatment for COVID-19Health Canada today granted authorization under the Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19 for the use of bamlanivimab (LY-CoV555) as a treatment for adults and pediatric patients 12 yearsRHEA-AIneutral
11/20/20 7:00 AMNYSE, Nasdaq : LLY, DTILLilly and Precision BioSciences Announce Genome Editing Research Collaboration and License AgreementEli Lilly and Company (NYSE: LLY) and Precision BioSciences, Inc. (Nasdaq: DTIL) today announced a research collaboration and exclusive license agreement to utilize Precision's proprietary ARCUS (R) genome editing platform for the researchRHEA-AIpositive
11/19/20 5:20 PMNYSE, Nasdaq : LLY, INCYBaricitinib Receives Emergency Use Authorization from the FDA for the Treatment of Hospitalized Patients with COVID-19Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today that the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the distribution and emergency use of baricitinib to be used in combination withRHEA-AInegative
11/19/20 6:45 AMNYSE : LLYLilly and Ypsomed collaborate to advance an automated insulin delivery system for people with diabetesEli Lilly and Company (NYSE: LLY) and Ypsomed (SWX: YPSN) announced today a non-exclusive, global agreement to advance an automated insulin delivery system as part of Lilly's connected diabetes solutions. Under the terms of theRHEA-AIvery positive
11/18/20 8:00 AMNYSE : LLYJardiance(R) reduced the risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and established cardiovascular disease in new analysis from the EMPA-REG OUTCOME(R) trialJardiance (R) (empagliflozin) reduced the risk of total (first plus recurrent) cardiovascular events compared with placebo, when both were given on top of standard of care, in adults with type 2 diabetes and established cardiovascularRHEA-AIneutral
11/12/20 12:35 PMNYSE : LLYLilly to Participate in Wolfe Research Virtual Healthcare ConferenceEli Lilly and Company (NYSE:LLY) will participate in the Wolfe Research Virtual Healthcare Conference on Wednesday, November 18, 2020. Joshua Smiley, senior vice president and Lilly's chief financial officer, will participate in a virtual fireside chat atRHEA-AIneutral
11/12/20 12:30 PMNYSE : LLYLilly to Participate in Bernstein Operational Decisions ConferenceEli Lilly and Company (NYSE:LLY) will participate in the Bernstein Operational Decisions Conference on Monday, November 16, 2020. Andrew Adams, Ph.D., vice president of new therapeutic modalities and scientific leader for Lilly's anti-COVID-19 platform,RHEA-AIneutral
